Terug
37
32
Dagbereik
€ 99,88
€ 103,35
52-Weeksbereik
€ 66,57
€ 211,00
Volume
802.780
50D / 200D Gem.
€ 136,39
/
€ 161,56
Vorige Slotkoers
€ 99,70
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (626 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 9,7 | 0,4 |
| P/B | 0,8 | 2,9 |
| ROE % | 8,4 | 3,8 |
| Net Margin % | 9,6 | 3,9 |
| Rev Growth 5Y % | 31,2 | 10,0 |
| D/E | 0,4 | 0,2 |
Koersdoel Analisten
Hold
€ 157,44
+56.9%
Low: € 100,00
High: € 222,00
Forward K/W
8,0
Forward WPA
€ 12,53
WPA Groei (sch.)
+0,0%
Omzet Sch.
8 B
Winstschattingen
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| FY2029 |
€ 15,69
€ 15,06 – € 16,00
|
8,9 B | 1 |
| FY2028 |
€ 14,98
€ 10,44 – € 18,43
|
8,7 B | 5 |
| FY2027 |
€ 13,57
€ 9,69 – € 16,94
|
8,3 B | 7 |
Belangrijkste Punten
Revenue grew 31,17% annually over 5 years — strong growth
Earnings grew 29,26% over the past year
Debt/Equity of 0,38 — conservative balance sheet
Generating 1,12B in free cash flow
P/E of 9,68 — trading at a low valuation
PEG of 0,76 suggests growth is underpriced
Groei
Revenue Growth (5Y)
31,17%
Revenue (1Y)1,99%
Earnings (1Y)29,26%
FCF Growth (3Y)62,97%
Kwaliteit
Return on Equity
8,44%
ROIC6,27%
Net Margin9,56%
Op. Margin13,26%
Veiligheid
Debt / Equity
0,38
Current Ratio1,26
Interest Coverage4,63
Waardering
P/E Ratio
9,68
P/B Ratio0,80
EV/EBITDA9,77
Dividend Yield0,00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 1,99% | Revenue Growth (3Y) | 3,43% |
| Earnings Growth (1Y) | 29,26% | Earnings Growth (3Y) | 25,15% |
| Revenue Growth (5Y) | 31,17% | Earnings Growth (5Y) | 24,65% |
| Profitability | |||
| Revenue (TTM) | 8,28B | Net Income (TTM) | 791,47M |
| ROE | 8,44% | ROA | 4,69% |
| Gross Margin | 29,42% | Operating Margin | 13,26% |
| Net Margin | 9,56% | Free Cash Flow (TTM) | 1,12B |
| ROIC | 6,27% | FCF Growth (3Y) | 62,97% |
| Safety | |||
| Debt / Equity | 0,38 | Current Ratio | 1,26 |
| Interest Coverage | 4,63 | Dividend Yield | 0,00% |
| Valuation | |||
| P/E Ratio | 9,68 | P/B Ratio | 0,80 |
| P/S Ratio | 0,93 | PEG Ratio | 0,76 |
| EV/EBITDA | 9,77 | Dividend Yield | 0,00% |
| Market Cap | 7,66B | Enterprise Value | 10,73B |
Income Statement
Annual, most recent first
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | 8,28B | 8,12B | 7,74B | 5,48B | 2,80B |
| Net Income | 791,47M | 612,34M | 505,30M | 153,19M | 327,81M |
| EPS (Diluted) | 9,53 | 7,40 | 6,13 | 2,25 | 6,24 |
| Gross Profit | 2,44B | 2,40B | 2,21B | 1,51B | 808,03M |
| Operating Income | 1,10B | 956,15M | 795,24M | 378,53M | 391,50M |
Balance Sheet
Annual, most recent first
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Total Assets | 16,88B | 16,99B | 17,19B | 17,39B | 3,44B |
| Total Liabilities | 7,35B | 7,75B | 8,69B | 9,32B | 1,59B |
| Shareholders' Equity | 9,52B | 9,24B | 8,50B | 8,07B | 1,85B |
| Total Debt | 3,60B | 3,94B | 4,83B | 5,65B | 433,61M |
| Cash & Equivalents | 538,79M | 378,10M | 288,77M | 752,21M | 840,31M |
| Current Assets | 3,53B | 3,41B | 3,23B | 2,94B | 2,10B |
| Current Liabilities | 2,80B | 2,83B | 2,69B | 2,48B | 1,12B |
Strategiescores
This stock passed the criteria for 2 strategies
Score = fit strength (0–100)
Rank = position among all matches
#491 of 820
#310 of 708
Recente Activiteit
Ingestapt
Deep Value Investing (Seth Klarman)
Mar 24, 2026
Ingestapt
Defensive Investing (Benjamin Graham)
Mar 24, 2026